Wellington Management Group LLP Buys New Shares in Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Wellington Management Group LLP bought a new stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 463,192 shares of the company's stock, valued at approximately $931,000. Wellington Management Group LLP owned about 0.23% of Taysha Gene Therapies as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. State Street Corp increased its holdings in shares of Taysha Gene Therapies by 4.5% during the third quarter. State Street Corp now owns 3,469,068 shares of the company's stock worth $6,973,000 after buying an additional 150,647 shares in the last quarter. MetLife Investment Management LLC raised its position in Taysha Gene Therapies by 81.9% in the third quarter. MetLife Investment Management LLC now owns 76,037 shares of the company's stock valued at $153,000 after purchasing an additional 34,243 shares during the last quarter. Charles Schwab Investment Management Inc. raised its position in Taysha Gene Therapies by 7.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 462,867 shares of the company's stock valued at $930,000 after purchasing an additional 33,123 shares during the last quarter. Intech Investment Management LLC bought a new stake in shares of Taysha Gene Therapies during the third quarter worth about $85,000. Finally, GSA Capital Partners LLP grew its holdings in shares of Taysha Gene Therapies by 64.7% during the third quarter. GSA Capital Partners LLP now owns 233,560 shares of the company's stock worth $469,000 after purchasing an additional 91,755 shares during the last quarter. Institutional investors and hedge funds own 77.70% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on TSHA. Chardan Capital reiterated a "buy" rating and set a $7.00 target price on shares of Taysha Gene Therapies in a research report on Thursday, November 14th. JMP Securities reiterated a "market outperform" rating and set a $5.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, November 12th. Cantor Fitzgerald reissued an "overweight" rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Tuesday, November 12th. Needham & Company LLC reaffirmed a "buy" rating and set a $6.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday, November 12th. Finally, Canaccord Genuity Group lifted their target price on Taysha Gene Therapies from $6.00 to $8.00 and gave the stock a "buy" rating in a report on Friday, November 15th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $6.63.

Taysha Gene Therapies Price Performance

Taysha Gene Therapies stock remained flat at $1.85 during trading hours on Friday. The company's stock had a trading volume of 6,162,874 shares, compared to its average volume of 2,869,229. The stock's fifty day moving average price is $2.14 and its 200 day moving average price is $2.32. Taysha Gene Therapies, Inc. has a 52-week low of $1.19 and a 52-week high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51. The firm has a market cap of $379.14 million, a price-to-earnings ratio of 2.94 and a beta of 0.79.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.